Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Multiple Sclerosis : Clinical and Laboratory Research
C C FordJ S Wolinsky

Abstract

The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing-remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole disease-modifying therapy. Two hundred and thirty-two patients received at least one GA dose since study initiation in 1991 (mITT cohort), and 100 (43%, Ongoing cohort) continued as of February 2008. Patients were evaluated every 6 months using the Expanded Disability Status Scale (EDSS). Mean GA exposures were 8.6 +/- 5.2, 4.81 +/- 3.69, and 13.6 +/- 1.3 years and mean disease durations were 17, 13, and 22 years for mITT, Withdrawn and Ongoing cohorts, respectively. For Ongoing patients, annual relapse rates (ARRs) maintained a decline from 1.12 +/- 0.82 at baseline to 0.25 +/- 0.34 per year; 57% had stable/improved EDSS scores (change < or = 0.5 points); 65% had not transitioned to secondary progressive multiple sclerosis (SPMS); 38%, 18%, and 3% reached EDSS 4, 6, and 8. For all patients on GA therapy (the mITT cohort), ARRs declined from 1.18 +/- 0.82 to 0.43 +/- 0.58 per year; 54% had stable/improved EDSS scores; 75% had not transitioned to SPMS; 39%, 23%, and 5% reached EDSS 4, 6, and 8. In ...Continue Reading

References

Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Sep 11, 2002·Neurology·J A CohenUNKNOWN IMPACT Investigators
Nov 13, 2002·Neurology·E FisherN A Simonian
Feb 1, 2003·Journal of the Neurological Sciences·Sandra Vukusic, Christian Confavreux
Nov 24, 2004·Neurology·Hillel PanitchUNKNOWN North American Study Group on Interferon beta-1b in Secondary Progressive MS
Dec 15, 2004·Acta Neurologica Scandinavica·K P JohnsonJ S Wolinsky
Jun 13, 2006·Multiple Sclerosis : Clinical and Laboratory Research·C C FordUNKNOWN Copaxone Study Group
Apr 21, 2007·Annals of Neurology·Maria TrojanoMaria Pia Amato
Dec 4, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G Ebers
Sep 10, 2009·Multiple Sclerosis : Clinical and Laboratory Research·D S Goodin, D Bates

❮ Previous
Next ❯

Citations

Jul 14, 2010·Archives of Neurology·Olaf StüveTodd N Eagar
Jun 4, 2011·Journal of Neurology·Dorothea Buck, Bernhard Hemmer
Jun 28, 2011·Current Neurology and Neuroscience Reports·Manuel Comabella, Koen Vandenbroeck
Dec 25, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Corey A McGraw, Fred D Lublin
Apr 24, 2013·Drugs·Rehiana AliPaolo Antonio Muraro
Jul 12, 2012·Therapeutic Advances in Neurological Disorders·Wanda Castro-BorreroElliot M Frohman
Oct 10, 2013·Practical Neurology·Claire M Rice
Nov 19, 2011·Multiple Sclerosis International·Mona Alkhawajah, Joel Oger
Sep 16, 2014·Multiple Sclerosis and Related Disorders·Daniel OntanedaRobert J Fox
Dec 11, 2013·Rheumatology·Marinka Twilt, Susanne M Benseler
Jun 6, 2013·Mediators of Inflammation·David H TianGila Moalem-Taylor
Sep 27, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Carmen Arnal-GarcíaUNKNOWN XPERIENCIA-5 Study Group
Apr 12, 2016·Multiple Sclerosis and Related Disorders·Douglas S GoodinEmmanuelle Waubant
Sep 8, 2010·Expert Review of Neurotherapeutics·Rina Aharoni
Mar 28, 2012·Expert Review of Neurotherapeutics·Kenneth P Johnson
Nov 19, 2011·Expert Review of Neurotherapeutics·Pietro IaffaldanoMaria Trojano
Dec 17, 2010·Expert Review of Neurotherapeutics·Douglas R JefferyKathy Tobias
Jun 10, 2014·Expert Opinion on Drug Metabolism & Toxicology·Michael D WieseCatherine O'Doherty
Jun 26, 2013·Expert Opinion on Drug Metabolism & Toxicology·Silvia Messina, Francesco Patti
May 21, 2013·Expert Opinion on Drug Metabolism & Toxicology·Michael D WieseCatherine O'Doherty
Oct 21, 2010·Expert Opinion on Drug Delivery·Brett E Phillips, Nick Giannoukakis
Nov 28, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Pierre DuquetteRobyn Schecter
Jul 4, 2012·Multiple Sclerosis and Related Disorders·Jw LindseyUNKNOWN the CombiRx Investigators Group
Dec 31, 2011·Journal of the Neurological Sciences·Xavier Montalban
Mar 29, 2011·Neurologic Clinics·Maria TrojanoMariangela D'Onghia
Sep 9, 2015·Multiple Sclerosis and Related Disorders·Tjalf ZiemssenBernd C Kieseier
Jan 10, 2012·Annals of the New York Academy of Sciences·Shiv SaidhaPeter A Calabresi
Feb 1, 2011·Annals of Neurology·Giancarlo ComiUNKNOWN FORTE Study Group
Oct 10, 2013·Clinical and Experimental Immunology·P S RommerO Stüve
Sep 17, 2015·Journal of Neurology, Neurosurgery, and Psychiatry·Ludwig KapposBernard M J Uitdehaag
Jul 6, 2014·Journal of Neuroscience Research·Spencer MooreSeema K Tiwari-Woodruff
Mar 9, 2013·Expert Opinion on Therapeutic Targets·Shlomo BakshiRiki Schwartz
Jan 15, 2015·Expert Opinion on Pharmacotherapy·Ron Milo
Dec 3, 2014·Neuroscience·M S Moehle, A B West

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.